menu
    • menu
    [{"orgOrder":0,"company":"Avidea Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"SNP-7\/8a","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Avidea Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Avidea Technologies \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Avidea Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Avidea Technologies","sponsor":"Barinthus Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Acquisition","leadProduct":"SNAPvax Cancer Vaccine","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avidea Technologies","amount2":0.040000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Intravenous","sponsorNew":"Avidea Technologies \/ Vaccitech plc","highestDevelopmentStatusID":"5","companyTruncated":"Avidea Technologies \/ Vaccitech plc"}]

    Find Clinical Drug Pipeline Developments & Deals by Avidea Technologies

    Menu

    Avidea Technologies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Avidea Technologies

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Avidea Technologies

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNAPvax Cancer Vaccine

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Barinthus Biotherapeutics

                            Deal Size : $40.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Vaccitech Acquires Avidea Technologies to Expand Product Pipeline and Strengthen Scientific Leadership in Immu...

                            Details : The acquisition of Avidea strengthens Vaccitech’s position as a leader in immunotherapies and vaccines including SNAPvax CV, using the SNAPvaxTM platform uses self-assembly to co-deliver multiple antigens and immunomodulators in nanoparticles of precis...

                            Brand Name : SNAPvax CV

                            Molecule Type : Vaccine

                            Upfront Cash : $12.5 million

                            December 13, 2021

                            Lead Product(s) : SNAPvax Cancer Vaccine

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Barinthus Biotherapeutics

                            Deal Size : $40.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Avidea Technologies

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Avidea Technologies

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNP-7/8a

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Avidea Technologies Utilizes GenScript's Synthesized Neoantigen Peptides for Novel Personalized Cancer Vaccine

                            Details : The groundbreaking peptide-based personalized cancer vaccine was shown to more efficiently induce T-cell responses against tumor neoantigens compared to traditional vaccines.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            January 15, 2020

                            Lead Product(s) : SNP-7/8a

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth